Patients, providers, researchers, clinicians, biopharmaceutical companies, regulatory reviewers and scientists will leave this 2.5-day conference with an understanding of:

- C-Path’s Rare and Orphan Disease Program’s current and future impact on drug development in rare diseases
- The Critical Path for Rare Neurodegenerative Diseases (CP-RND) initiative’s first year impact and highlights
- How RDCA-DAP has been enhanced in the last year, and how the platform informs rare disease drug development
- Transversal solutions to address bottlenecks in drug development

**When:** September 11-13, 2023

**Where:** Washington Marriott at Metro Center

Washington, DC 20005
Building a rare and orphan disease community that works. Together.